Trial Profile

A retrospective study evaluating efficacy of direct acting antiviral agents in hepatitis C patients.

Status: Active, no longer recruiting

Phase of Trial: Phase IV

Latest Information Update: 09 Mar 2017

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Daclatasvir/sofosbuvir (Primary) ; Dasabuvir (Primary) ; Ledipasvir/sofosbuvir (Primary) ; Ombitasvir/paritaprevir/ritonavir (Primary) ; Ribavirin (Primary) ; Simeprevir (Primary)
Indications Hepatitis C
Focus Therapeutic Use

Most Recent Events

09 Mar 2017 New trial record
01 Feb 2017 Results published in the International Journal of Clinical PharmacyConference: 45th ESCP-NSF International Symposium on Clinical Pharmacy: Clinical Pharmacy Tackling Inequalities and Access to Health Care Norway

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com